Which has preferable earnings and valuation, PHVS or CTNM?

Pharvaris is trading at a lower price-to-earnings ratio than Contineum Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pharvaris N/A N/A -$198.79M -$3.18 N/A Contineum Therapeutics N/A N/A -$59.98M -$1.95 N/A

Is PHVS or CTNM more profitable?

Contineum Therapeutics' return on equity of -27.09% beat Pharvaris' return on equity. Company Net Margins Return on Equity Return on Assets Pharvaris N/A -67.56% -61.13% Contineum Therapeutics N/A -27.09% -25.64%

Does the media favor PHVS or CTNM?

In the previous week, Pharvaris had 11 more articles in the media than Contineum Therapeutics. MarketBeat recorded 13 mentions for Pharvaris and 2 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 1.43 beat Pharvaris' score of -0.09 indicating that Contineum Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 1 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Contineum Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, CTNM or TRVI?

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Contineum Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Contineum Therapeutics N/A N/A -$59.98M -$1.95 N/A Trevi Therapeutics N/A N/A -$42.76M -$0.32 N/A

Is CTNM or TRVI more profitable?

Trevi Therapeutics' return on equity of -24.53% beat Contineum Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Contineum Therapeutics N/A -27.09% -25.64% Trevi Therapeutics N/A -24.53% -23.37%

Do analysts prefer MESO or CTNM?

Contineum Therapeutics has a consensus price target of $20.00, suggesting a potential upside of 52.79%. Given Contineum Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Contineum Therapeutics is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mesoblast 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Contineum Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is MESO or CTNM more profitable?

Mesoblast's return on equity of 0.00% beat Contineum Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Mesoblast N/A N/A N/A Contineum Therapeutics N/A -27.09% -25.64%

Does the media refer more to MESO or CTNM?

In the previous week, Mesoblast and Mesoblast both had 2 articles in the media. Contineum Therapeutics' average media sentiment score of 1.43 beat Mesoblast's score of 0.93 indicating that Contineum Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesoblast 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Contineum Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ANIP or CTNM?

In the previous week, ANI Pharmaceuticals had 1 more articles in the media than Contineum Therapeutics. MarketBeat recorded 3 mentions for ANI Pharmaceuticals and 2 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 1.43 beat ANI Pharmaceuticals' score of 1.14 indicating that Contineum Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ANI Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Contineum Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CTNM or STOK?

In the previous week, Stoke Therapeutics had 1 more articles in the media than Contineum Therapeutics. MarketBeat recorded 3 mentions for Stoke Therapeutics and 2 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 1.43 beat Stoke Therapeutics' score of 1.18 indicating that Contineum Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Contineum Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stoke Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Contineum Therapeutics (CTNM) Competitors

$13.09 -0.40 (-2.97%)

Closing price 04:00 PM Eastern

Extended Trading

$13.13 +0.04 (+0.31%)

As of 04:10 PM Eastern

Compare

CTNM vs. PHVS, TRVI, MESO, ANIP, and STOK

Should you buy Contineum Therapeutics stock or one of its competitors? MarketBeat compares Contineum Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Contineum Therapeutics include Pharvaris (PHVS), Trevi Therapeutics (TRVI), Mesoblast (MESO), ANI Pharmaceuticals (ANIP), and Stoke Therapeutics (STOK). These companies are all part of the "pharmaceutical products" industry.

How does Contineum Therapeutics compare to Pharvaris?

Pharvaris (NASDAQ:PHVS) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

Pharvaris is trading at a lower price-to-earnings ratio than Contineum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A
Contineum Therapeutics	N/A	N/A	-$59.98M	-$1.95	N/A

Contineum Therapeutics' return on equity of -27.09% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-67.56%	-61.13%
Contineum Therapeutics	N/A	-27.09%	-25.64%

Pharvaris has a beta of -2.35, indicating that its stock price is 335% less volatile than the broader market. Comparatively, Contineum Therapeutics has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market.

In the previous week, Pharvaris had 11 more articles in the media than Contineum Therapeutics. MarketBeat recorded 13 mentions for Pharvaris and 2 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 1.43 beat Pharvaris' score of -0.09 indicating that Contineum Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	1 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Contineum Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pharvaris presently has a consensus target price of $49.18, indicating a potential upside of 69.01%. Contineum Therapeutics has a consensus target price of $20.00, indicating a potential upside of 52.79%. Given Pharvaris' stronger consensus rating and higher possible upside, equities analysts clearly believe Pharvaris is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Contineum Therapeutics beats Pharvaris on 7 of the 11 factors compared between the two stocks.

How does Contineum Therapeutics compare to Trevi Therapeutics?

Contineum Therapeutics (NASDAQ:CTNM) and Trevi Therapeutics (NASDAQ:TRVI) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

In the previous week, Contineum Therapeutics had 1 more articles in the media than Trevi Therapeutics. MarketBeat recorded 2 mentions for Contineum Therapeutics and 1 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 1.89 beat Contineum Therapeutics' score of 1.43 indicating that Trevi Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Contineum Therapeutics	Positive
Trevi Therapeutics	Very Positive

Contineum Therapeutics has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market. Comparatively, Trevi Therapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market.

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Contineum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Contineum Therapeutics	N/A	N/A	-$59.98M	-$1.95	N/A
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A

Contineum Therapeutics presently has a consensus price target of $20.00, suggesting a potential upside of 52.79%. Trevi Therapeutics has a consensus price target of $22.90, suggesting a potential upside of 64.16%. Given Trevi Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Trevi Therapeutics is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00

Trevi Therapeutics' return on equity of -24.53% beat Contineum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Contineum Therapeutics	N/A	-27.09%	-25.64%
Trevi Therapeutics	N/A	-24.53%	-23.37%

95.8% of Trevi Therapeutics shares are owned by institutional investors. 11.3% of Contineum Therapeutics shares are owned by insiders. Comparatively, 18.3% of Trevi Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Trevi Therapeutics beats Contineum Therapeutics on 12 of the 14 factors compared between the two stocks.

How does Contineum Therapeutics compare to Mesoblast?

Mesoblast (NASDAQ:MESO) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

Contineum Therapeutics has a consensus price target of $20.00, suggesting a potential upside of 52.79%. Given Contineum Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Contineum Therapeutics is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Mesoblast has a beta of 2.09, indicating that its stock price is 109% more volatile than the broader market. Comparatively, Contineum Therapeutics has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market.

1.4% of Mesoblast shares are held by institutional investors. 18.8% of Mesoblast shares are held by company insiders. Comparatively, 11.3% of Contineum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Contineum Therapeutics has lower revenue, but higher earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Contineum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$65.38M	29.42	-$102.14M	-$0.54	N/A
Contineum Therapeutics	N/A	N/A	-$59.98M	-$1.95	N/A

Mesoblast's return on equity of 0.00% beat Contineum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
Contineum Therapeutics	N/A	-27.09%	-25.64%

In the previous week, Mesoblast and Mesoblast both had 2 articles in the media. Contineum Therapeutics' average media sentiment score of 1.43 beat Mesoblast's score of 0.93 indicating that Contineum Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesoblast	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Contineum Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Mesoblast beats Contineum Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Contineum Therapeutics compare to ANI Pharmaceuticals?

ANI Pharmaceuticals (NASDAQ:ANIP) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

76.1% of ANI Pharmaceuticals shares are held by institutional investors. 8.1% of ANI Pharmaceuticals shares are held by company insiders. Comparatively, 11.3% of Contineum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

ANI Pharmaceuticals has a net margin of 9.98% compared to Contineum Therapeutics' net margin of 0.00%. ANI Pharmaceuticals' return on equity of 27.51% beat Contineum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	9.98%	27.51%	10.02%
Contineum Therapeutics	N/A	-27.09%	-25.64%

In the previous week, ANI Pharmaceuticals had 1 more articles in the media than Contineum Therapeutics. MarketBeat recorded 3 mentions for ANI Pharmaceuticals and 2 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 1.43 beat ANI Pharmaceuticals' score of 1.14 indicating that Contineum Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ANI Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Contineum Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ANI Pharmaceuticals has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market. Comparatively, Contineum Therapeutics has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market.

ANI Pharmaceuticals currently has a consensus target price of $107.33, indicating a potential upside of 39.92%. Contineum Therapeutics has a consensus target price of $20.00, indicating a potential upside of 52.79%. Given Contineum Therapeutics' higher possible upside, analysts plainly believe Contineum Therapeutics is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.63
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

ANI Pharmaceuticals has higher revenue and earnings than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$883.37M	1.98	$78.34M	$3.95	19.42
Contineum Therapeutics	N/A	N/A	-$59.98M	-$1.95	N/A

Summary

ANI Pharmaceuticals beats Contineum Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Contineum Therapeutics compare to Stoke Therapeutics?

Contineum Therapeutics (NASDAQ:CTNM) and Stoke Therapeutics (NASDAQ:STOK) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

Contineum Therapeutics has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -529.20%. Contineum Therapeutics' return on equity of -27.09% beat Stoke Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Contineum Therapeutics	N/A	-27.09%	-25.64%
Stoke Therapeutics	-529.20%	-48.84%	-42.27%

Contineum Therapeutics has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.17, indicating that its stock price is 17% more volatile than the broader market.

Contineum Therapeutics currently has a consensus price target of $20.00, indicating a potential upside of 52.79%. Stoke Therapeutics has a consensus price target of $41.83, indicating a potential upside of 37.29%. Given Contineum Therapeutics' higher possible upside, equities analysts plainly believe Contineum Therapeutics is more favorable than Stoke Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Stoke Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Stoke Therapeutics has higher revenue and earnings than Contineum Therapeutics. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Contineum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Contineum Therapeutics	N/A	N/A	-$59.98M	-$1.95	N/A
Stoke Therapeutics	$184.42M	10.29	-$6.89M	-$2.81	N/A

In the previous week, Stoke Therapeutics had 1 more articles in the media than Contineum Therapeutics. MarketBeat recorded 3 mentions for Stoke Therapeutics and 2 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 1.43 beat Stoke Therapeutics' score of 1.18 indicating that Contineum Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Contineum Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stoke Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Contineum Therapeutics beats Stoke Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Contineum Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTNM vs. The Competition

Export

Metric	Contineum Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$504.34M	$3.40B	$6.43B	$12.56B
Dividend Yield	N/A	2.28%	2.69%	5.30%
P/E Ratio	-6.71	17.92	21.32	26.62
Price / Sales	N/A	333.37	551.83	113.73
Price / Cash	N/A	54.19	27.44	37.60
Price / Book	1.87	6.84	9.95	6.88
Net Income	-$59.98M	$24.15M	$3.56B	$336.73M
7 Day Performance	-5.56%	1.93%	2.12%	4.19%
1 Month Performance	N/A	N/A	N/A	-0.08%
1 Year Performance	261.60%	62.98%	36.32%	40.26%

Contineum Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTNM Contineum Therapeutics	3.543 of 5 stars	$13.09 -3.0%	$20.00 +52.8%	+272.7%	$504.34M	N/A	N/A	31	Positive News
PHVS Pharvaris	3.5347 of 5 stars	$29.71 +2.6%	$49.18 +65.5%	+82.5%	$1.94B	N/A	N/A	30	Short Interest Decrease
TRVI Trevi Therapeutics	3.7814 of 5 stars	$13.61 +2.8%	$22.90 +68.2%	+117.5%	$1.93B	N/A	N/A	20	Positive News
MESO Mesoblast	1.2079 of 5 stars	$14.45 -0.7%	N/A	+45.1%	$1.87B	$65.38M	N/A	80
ANIP ANI Pharmaceuticals	3.6081 of 5 stars	$82.18 +2.3%	$107.33 +30.6%	+32.5%	$1.87B	$883.37M	20.81	600	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTNM) was last updated on 6/1/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Contineum Therapeutics (CTNM) Competitors

CTNM vs. PHVS, TRVI, MESO, ANIP, and STOK

How does Contineum Therapeutics compare to Pharvaris?

Summary

How does Contineum Therapeutics compare to Trevi Therapeutics?

Summary

How does Contineum Therapeutics compare to Mesoblast?

Summary

How does Contineum Therapeutics compare to ANI Pharmaceuticals?

Summary

How does Contineum Therapeutics compare to Stoke Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTNM vs. The Competition

Contineum Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Contineum Therapeutics (CTNM) Competitors

CTNM vs. PHVS, TRVI, MESO, ANIP, and STOK

How does Contineum Therapeutics compare to Pharvaris?

Which has preferable earnings and valuation, PHVS or CTNM?

Is PHVS or CTNM more profitable?

Which has more risk & volatility, PHVS or CTNM?

Does the media favor PHVS or CTNM?

Do analysts recommend PHVS or CTNM?

Summary

How does Contineum Therapeutics compare to Trevi Therapeutics?

Does the media prefer CTNM or TRVI?

Which has more volatility and risk, CTNM or TRVI?

Which has preferable earnings and valuation, CTNM or TRVI?

Do analysts prefer CTNM or TRVI?

Is CTNM or TRVI more profitable?

Do insiders and institutionals hold more shares of CTNM or TRVI?

Summary

How does Contineum Therapeutics compare to Mesoblast?

Do analysts prefer MESO or CTNM?

Which has more risk & volatility, MESO or CTNM?

Do insiders & institutionals hold more shares of MESO or CTNM?

Which has higher earnings and valuation, MESO or CTNM?

Is MESO or CTNM more profitable?

Does the media refer more to MESO or CTNM?

Summary

How does Contineum Therapeutics compare to ANI Pharmaceuticals?

Do institutionals and insiders have more ownership in ANIP or CTNM?

Is ANIP or CTNM more profitable?

Does the media prefer ANIP or CTNM?

Which has more volatility and risk, ANIP or CTNM?

Do analysts recommend ANIP or CTNM?

Which has preferable valuation and earnings, ANIP or CTNM?

Summary

How does Contineum Therapeutics compare to Stoke Therapeutics?

Is CTNM or STOK more profitable?

Which has more volatility & risk, CTNM or STOK?

Do analysts recommend CTNM or STOK?

Which has higher valuation and earnings, CTNM or STOK?

Does the media prefer CTNM or STOK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTNM vs. The Competition

Contineum Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools